Verrica Pharmaceuticals Update: Company Announces First Sale of YCANTH to FFF Enterprises

FFF Enterprises is Verrica's exclusive distribution partner.

Verrica Pharmaceuticals Inc. announced the first commercial sale of YCANTH to its exclusive distributor, FFF Enterprises Inc. (FFF).

 “As one of the nation’s most trusted specialty pharmaceutical distributors, FFF is well positioned to help Verrica introduce YCANTH™ as the first FDA-approved therapy for the treatment of molluscum contagiosum in the U.S. With this first commercial sale of YCANTH, we continue to execute our launch plans and we look forward to providing a more detailed update on our progress in November,” says Ted White, President and Chief Executive Officer of Verrica Pharmaceuticals, in a news release.

“FFF has a well-established reputation for partnering with companies like Verrica that develop innovative products to address a significant unmet medical need,” adds Patrick M. Schmidt, the founder and Chief Executive Officer of FFF. “As the first FDA-approved product to treat molluscum, YCANTH clearly addresses a significant unmet need for the millions of children and adults with this viral skin disease. Through this distribution partnership with Verrica, we plan to introduce YCANTH into the U.S. dermatology and pediatric communities so that millions of patients can finally gain access to the first FDA-approved therapy for the treatment of molluscum.”

“FFF has consistently demonstrated true partnership and customer centricity that we value at Verrica,” says Joe Bonaccorso, Chief Commercial Officer of Verrica Pharmaceuticals. “With our sales and marketing team fully in place, we are excited to work in partnership with FFF so this large and underserved patient population can benefit from YCANTH therapy.”